Clinical Improvement in Pulmonary Arterial Hypertension (PAH) Patients Transitioning from Selexipag to Oral Treprostinil: Interim Results from the ADAPT Registry

被引：0

作者：

Lachant, D. ^{[1
]}

Minkin, R. ^{[2
]}

Swisher, J. ^{[3
]}

Mogri, M. ^{[4
]}

Zolty, R. ^{[5
]}

Shelton, D. ^{[6
]}

Seaman, S. ^{[7
]}

Broderick, M. ^{[7
]}

Sahay, S. ^{[8
]}

机构：

[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[2] NewYork Presbyterian Brooklyn Methodist Hosp, Brooklyn, NY USA

[3] Ft Sanders Reg Med Ctr, Knoxville, TN USA

[4] Baylor Scott & White Pulm & Crit Care Specialists, Dallas, TX USA

[5] Univ Nebraska Med Ctr, Omaha, NE USA

[6] Univ N Carolina, Chapel Hill, NC 27515 USA

[7] United Therapeut Corp, Res Triangle Pk, NC USA

[8] Houston Methodist Lung Ctr, Houston, TX USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2022年 / 205卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A3592

引用

页数：2

共 50 条

[41] Survival in patients with pulmonary arterial hypertension: data from the registry - single PAH centre
Selimovic, N.
Andersson, B.
Bech-Hanssen, O.
Rundqvist, B.
[J]. EUROPEAN HEART JOURNAL, 2011, 32 : 437 - 437
[42] Safely Transitioning from Inhaled Iloprost to Inhaled Treprostinil Sodium - Results from a Multicenter Open-Label Study in Patients with Pulmonary Arterial Hypertension
Bourge, R. C.
Tapson, V. F.
Safdar, Z.
Benza, R. L.
Channick, R. N.
Rosenzweig, E. B.
Shapiro, S.
McSwain, C. S.
Gotzkowsky, A.
Nelsen, A.
Rubin, L. J.
[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S71 - S72
[43] One year experience with intravenous treprostinil in pulmonary arterial hypertension (PAH) patients
McLaughlin, VV
Barst, R
Gomberg-Maitland, M
Tapson, V
Krichman, A
Widlitz, A
Rich, S
Benza, R
[J]. CHEST, 2005, 128 (04) : 160S - 160S
[44] Understanding the Pharmacokinetics of Oral Treprostinil in Patients With Pulmonary Arterial Hypertension
Perez, Vinicio A. de Jesus
[J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 61 (06) : 471 - 473
[45] Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
Corboz, Michel R.
Plaunt, Adam J.
Malinin, Vladimir S.
Li, Zhili
Gauani, Helena
Chun, Donald
Cipolla, David
Perkins, Walter R.
Chapman, Richard W.
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 383 (01): : 103 - 116
[46] INTERIM DATA FROM THE ADAPT REGISTRY: REAL-WORLD TOLERABILITY AND MANAGEMENT OF ADVERSE EVENTS IN PATIENTS RECEIVING ORAL TREPROSTINIL
Kingrey, John
Swisher, John
Ravichandran, Ashwin
Gordon, Joshiah
Gordon, Kathryn
Broderick, Meredith
Carrell, Grace
Lee, Dasom
Sahay, Sandeep
[J]. CHEST, 2020, 158 (04) : 2169A - 2170A
[47] Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension
Radosevich, John J.
DeChristopher, Audra
Irandost, Maykel
Fann, Jade
Feldman, Jeremy
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (15) : 1208 - 1212
[48] Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension
Keogh, Anne M.
Jabbour, Andrew
Weintraub, Robert
Brown, Karen
Hayward, Chris S.
Macdonald, Peter S.
[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (11): : 1079 - 1083
[49] Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series
Ackerbauer, Kimberly A.
Tandon, Rajive
[J]. JOURNAL OF PHARMACY PRACTICE, 2018, 31 (02) : 163 - 166
[50] Long-Term Experience and Safety of Transitioning from Subcutaneous Treprostinil to Oral Selexipag in the High-Risk Pulmonary Hypertension Patient: A Case Report
Ting, Yung-Hsiang
Yu, Min-Wei
Wu, Yih-Jer
Wu, Shu-Hao
[J]. ACTA CARDIOLOGICA SINICA, 2023, 39 (03) : 492 - 496

← 1 2 3 4 5 →